INFI.Q Stock Overview
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Infinity Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.26 |
| 52 Week Low | US$0.000001 |
| Beta | 1.33 |
| 11 Month Change | -99.00% |
| 3 Month Change | -99.96% |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
Nov 10
Infinity Pharmaceuticals: Waiting For A Deal
Sep 08Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
May 23We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely
Dec 29Investigating Infinity Pharmaceuticals
Nov 25Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans
Jul 18Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now
Jun 03Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?
Apr 13Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?
Feb 19Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?
Jan 15
Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer
Jan 06Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?
Dec 11Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium
Dec 09Infinity Pharmaceutical Reaching Vital New Staging Posts
Dec 01Shareholder Returns
| INFI.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | -100.0% | 16.1% | 31.6% |
Return vs Industry: INFI.Q underperformed the US Biotechs industry which returned 16% over the past year.
Return vs Market: INFI.Q underperformed the US Market which returned 31% over the past year.
Price Volatility
| INFI.Q volatility | |
|---|---|
| INFI.Q Average Weekly Movement | 188.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INFI.Q's share price has been volatile over the past 3 months.
Volatility Over Time: INFI.Q's weekly volatility has increased from 89% to 189% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 30 | Seth Tasker | www.infi.com |
Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company’s product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc. Fundamentals Summary
| INFI.Q fundamental statistics | |
|---|---|
| Market cap | US$90.00 |
| Earnings (TTM) | -US$40.95m |
| Revenue (TTM) | US$2.57m |
0.0x
P/S Ratio0.0x
P/E RatioIs INFI.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INFI.Q income statement (TTM) | |
|---|---|
| Revenue | US$2.57m |
| Cost of Revenue | US$28.53m |
| Gross Profit | -US$25.96m |
| Other Expenses | US$14.99m |
| Earnings | -US$40.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -1,010.35% |
| Net Profit Margin | -1,593.93% |
| Debt/Equity Ratio | -127.9% |
How did INFI.Q perform over the long term?
See historical performance and comparison